Top 100 Drugs Flashcards
(110 cards)
5-alpha reductase inhibitors
- Mechanism of action = Inhibition of 5-alpha reductase → ↓ conversion of testosterone to DHT → ↓ intraprostatic DHT levels → ↓ prostatic growth and ↑ prostatic apoptosis and involution → improvement of LUTS
- Main indications = enlarged prostate gland (benign prostatic hyperplasia leading to lower urinary tract symptoms) and male pattern hair loss (Androgenetic alopecia in men)
- Contraindications = caution around pregnant women (absorbed through skin)
- Route of admin = mouth
- Adverse effects = sexual dysfunction (e.g., erectile dysfunction, decreased libido, ejaculatory dysfunction), gynecomastia, breast cancer, suicidal thoughts
- Examples = Finasteride, Dutasteride
Monoclonal antibodies
- Mechanism of action = Monodonal antibodies (mAbs) are generated by immunising animals with target proteins. B cells are selected and immortalised to create clones that produce homogenous antibodies against specific regions (epitopes) on the target protein. As animal antibodies are immunogenic in humans, their structure is altered by genetic engineering to make them more similar (humanised) or identical to human antibodies. Binding of mAbs to their target epitope inhibits or activates biological processes that leads to therapeutic effect. In inflammatory disease, mAbs suppress excessive immune responses by targeting components of the immune system. In cancer, mAbs may target tumour cells directly, enhance anti-tumour immune responses, alter the tumour microenvironment (e.g. inhibiting angiogenesis) or deliver targeted chemotherapy or radioisotopes. In infection, mAbs neutralise pathogens. In other conditions, mAbs target key proteins in disease pathology. For example, denosumab inhibits RANKL, an essential osteoclast protein, thereby decreasing bone resorption in the treatment of osteoporosis.
- Indications =
1) Immune-mediated disorders, e.g. rheumatoid arthritis, psoriasis, psoriatic arthritis, inflammatory bowel disease.
2) Allergic disorders, e.g. asthma, eczema, rhinitis with polyps.
3) Precision treatment of cancers, including haematological (e.g. leukaemias, lymphomas) and solid tumours (e.g. breast and lung cancer).
5) Prevention of adverse outcomes in high-risk COVID-19 disease or respiratory syncytial virus infections.
6) Treatment of some long-term conditions with a target amenable to immune manipulation, e.g. osteoporosis, hypercholesterolaemia, migraine, sickle cell disease, haemophilia A. - Contraindications = Cautions for individual mAbs vary, so refer to the BNF and seek local specialist guidance. Active and latent infection, including with tuberculosis and hepatitis B or C, should be treated before starting long-term treatment with a mAb that can cause immune suppression.
- Route of admin = mAbs have large size, poor membrane permeability, and are digested by gastric proteases. They are therefore administered parenterally by IV, SC or IM injection.
- Adverse reactions = immediate and delayed hypersensitivity reactions, e.g. local injection reaction, fever, urticaria. Adverse effects of individual mAbs depend on their biological actions. mAbs that target the immune system can cause immune imbalance, e.g. immunosuppression, increasing the risk of severe infection or cancer, or overstimulation, leading to development of a new autoimmune condition. Generally, however, due to their precisely targeted effect, monoclonal antibodies are often better tolerated than conventional cytotoxic and immune suppressing treatments.
- Examples = infliximab, adalimumab, denosumab, rituximab, omalizumab
Allopurinol
- Mechanism of action = Allopurinol is a purine analogue that inhibits xanthine oxidase. Xanthine oxidase metabolises xanthine (produced from purines) to uric acid. Inhibition of xanthine oxidase lowers plasma uric acid concentrations and reduces precipitation of uric acid in the joints or kidneys.
- Main indications =
1) To prevent recurrent attacks of gout, particularly in people with two or more attacks per year or with signs of joint damage or renal impairment.
2) To prevent uric acid and calcium oxalate renal stones.
3) To prevent hyperuricaemia and tumour lysis syndrome due to chemotherapy. - Contraindications = Allopurinol should not be started during an *acute attack of gout, but can be continued if already established, to avoid sudden fluctuations in serum uric acid levels. *Recurrent skin rash or signs of more *severe hypersensitivity to allopurinol are contraindications to therapy. Allopurinol is metabolised in the liver and excreted by the kidney. The dose should therefore be reduced in severe *renal impairment or *hepatic impairment. The active metabolite (mercaptopurine) of the pro-drug A azathioprie is metabolised by xanthine oxidase. Concurrent administration with allopurinol increases the risk of azathioprine toxicity. Co-prescription of allopurinol with *ACE inhibitors or thiazides increases the risk of hypersensitivity reactions, and with amoxicillin increases the risk of skin rash.
- Route of admin = mouth
- Adverse effects = Allopurinol is generally well tolerated. However, starting allopurinol can trigger or worsen an acute attack of gout, possibly through effects on preformed crystals. The risk of triggering an attack may be reduced by co-prescription of an NSAID or colchicine in the initiation phase. The most common side effect is a skin rash, which may be mild or may indicate a more serious hypersensitivity reaction such as Stevens-Johnson syndrome or toxic epidermal necrolysis. Allopurinol hypersensitivity syndrome is a rare, life-threatening reaction to allopurinol that can include fever, eosinophila. lymphadenopathy, and involvement of other organs, such as the liver and skin. If allopurinol is not tolerated or is contraindicated, febuxostat (a non-purine xanthine oxidase inhibitor) is an alternative second-line therapy. However, a prior history of hypersensitivity to allopurinol is associated with potential hypersensitivity to febuxostat.
- Examples = allopurinol
Acetylcholinesterase inhibitors
- Mechanism of action = Acetylcholine is an important CNS neurotransmiter, which is essential to many brain functions including learning and memory. A decrease in activity of the brain’s cholinergic system is seen in Alzheimer’s disease and in the form of dementia associated with Parkinson’s disease. These drugs inhibit the cholinesterase enzymes that break down acetylcholine in the CNS. It is thought that by increasing the availability of acetylcholine for neurotransmission, they improve cognitive function and reduce the rate of cognitive decline. However, recovery of function in people with these conditions on starting treatment is modest and not universal.
- Main indications =
1) Mild to moderate dementia in Alzheimer’s disease
2) Mild to moderate dementia in Parkinson’s disease (Rivastigmine) - Contraindications = Acetylcholinesterase inhibitors should be used with caution in people with & asthma and *COPD and those at risk of developing *peptic ulcers. They should be avoided in people with *heart block or *sick sinus syndrome. Rivastigmine may worsen tremor in those with *Parkinson’s disease.
- Route of admin = mouth
- Adverse effects = GI upset is the most common adverse effect, arising from increased cholinergic activity in the peripheral nervous system. This may resolve over time. People with asthma or COPD may experience an exacerbation of bronchospasm. Less common, but serious, peripheral effects include peptic ulcers and bleeding, bradycardia, and heart block. Central cholinergic effects may induce hallucinations and altered/aggressive behaviour. These resolve with reduction of dose or discontinuation of therapy. There is a small risk of extrapyramidal symptoms and neuroleptic malignant syndrome.
- Examples = Rivastigmine, Donepezil
Antiplatelet drugs, aspirin
- Mechanism of action = Thrombotic events occur when platelet-rich thrombus forms in atheromatous arteries and occludes the circulation. Aspirin irreversibly inhibits cyclooxygenase (COX) to reduce production of the pro-aggregatory factor thromboxane from arachidonic acid, reducing platelet aggregation and the risk of arterial occlusion. The antiplatelet effect of aspirin occurs at low doses and lasts for the lifetime of a platelet (7-10 days), as platelets do not have nuclei to allow synthesis of new COX. As a result, the effect of aspirin only wears off as new platelets are made.
- Main indications =
1) For treatment of ACS and acute ischaemic stroke, where rapid inhibition of platelet aggregation can prevent or limit arterial thrombosis and reduce subsequent mortaity.
2) For secondary prevention of major adverse cardiovascular events in ischaemic heart disease, cerebrovascular disease, or peripheral vascular disease.
3) At higher doses, aspirin can be used in mild-to-moderate pain and ever, although paracetamol and other NSAIDs are usually preferred. - Contraindications = Aspirin should not be given to *children aged under 16 years due to the risk of Reye’s syndrome, a rare but life-threatening illness that principally affects the liver and brain. It should not be taken by people with *aspirin hypersensitivity, i.e. who have had bronchospasm or other allergic symptoms triggered by exposure to aspirin or another NSAID. However, aspirin is not routinely contraindicated in asthma.
Aspirin should be avoided in the third trimester of pregnancy when prostaglandin inhibition may lead to premature closure of the ductus arteriosus. Aspirin should be used with caution in *peptic ulceration (consider gastroprotection) and *gout, where it may trigger an attack. Caution is required in some cases, e.g. ACS, when administered with other antiplatelet agents ,e.g. clopidogrel, and *anticoagulants, e.g. heparin, warfarin. - Route of admin = mouth (after food to minimise gastric irritation)
- Adverse effects =
The most common adverse effect of aspirin is Gl upset. More serious effects include peptic ulceration and hemorrhage, and hypersensitivity reactions including bronchospasm. In regular high-dose therapy, aspirin can cause tinnitus. Aspirin overdose is life-threatening. Features include hyperventilation, hearing changes, metabolic acidosis, and confusion, followed by convulsions, cardiovascular collapse, and respiratory arrest. - Examples = Aspirin
α-blockers
- Mechanism of action =
Although often described using the broad term ‘a-blocker, most drugs in this class (including doxazosin, tamsulosin, and alfuzosin) are highly selective for a1-adrenoceptors. These are found mainly in smooth muscle, including in blood vessels and the urinary tract (the bladder neck and prostate in particular). Stimulation induces contraction; blockade induces relaxation. Inhibiting the a1-adrenoceptor therefore causes vasodilation and a fall in blood pressure (BP) and reduces resistance to urine outflow from the bladder. - Main indications =
1) As a first-line medical option to improve lower urinary tract symptoms (LUTS) in benign prostatic enlargement, when lifestyle changes are insufficient or voiding symptoms are moderate to severe.
5a-reductase inhibitors may be added in selected cases. Surgical treatment is also an option, particularly if there is evidence of urinary tract damage (e.g. hydronephrosis).
2) As an add-on treatment in resistant hypertension, when other medicines (e.g. calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, thiazide diuretics) are insufficient. - Contraindications = Avoid a-blockers in people with existing & postural hypotension.
- Route of admin = oral (best taken at night)
- Adverse effects = Predictably from their effects on vascular tone, a1-blockers can cause postural hypotension, dizziness, and syncope. This is particular prominent after the first dose.
- Examples = Tamsulosin, Doxazosin, Alfuzosin
Antiemetics, serotonin 5-HT3-receptor antagonists
- Mechanism of action = Nausea and vomiting are triggered by gut irritation, drugs, motion, vestibular disorders, and higher stimuli (sights, smells, emotions). The pathways converge on a ‘vomiting centre’ in the medulla, which receives inputs from the chemoreceptor trigger zone (CTZ), the vagus nerve, the vestibular system and higher centres. Serotonin (5-hydroxytryptamine (5-HT)) plays an important role in two of these pathways. First, there is a high density of 5-HT, receptors in the CTZ, which are responsible for sensing emetogenic substances in the blood (e.g. drugs). Second, 5-HT is the key neurotransmitter released by the gut in response to emetogenic stimuli. Acting on 5-HT3 receptors, it stimulates the vagus nerve, which in turn activates the vomiting centre via the solitary tract nucleus. Of note, 5-HT is not involved in communication between the vestibular system and the vomiting centre. Thus 5-HT3 antagonists are effective against nausea and vomiting as a result of CTZ stimulation (e.g. drugs) and visceral stimuli (gut infection, radiotherapy), but not in motion sickness.
- Main indications =
1) Prophylaxis and treatment of nausea and vomiting, particularly in the context of general anaesthesia and chemotherapy. - Contraindications = 5-HT3 antagonists should be used with caution in people with *prolonged QT interval. If there is a risk factor for this, review an electrocardiogram (ECG) before prescribing. Ondansetron is not recommended in the first trimester of *pregnancy, as it has been linked in epidemiological studies to an increased risk of cleft lip and palate.
- Route of admin = mouth, rectum, intramuscular injection, intravenous infusion
- Adverse effects =
Constipation, headache, and flushing are common. Serious indorse effects are rare. There is a small risk that 5-HT3 antagonsts may prolong the QT interval, although this is usually evident only at high doses (e.g. >16 mg ondansetron). - Examples = Ondansetron, granisetron
Antiviral drugs, aciclovir
- Mechanism of action = The herpesvirus family includes herpes simplex 1 and 2 and varicella-zoster. These viruses contain double-stranded DNA, which requires a herpes-specific DNA polymerase for the virus to replicate. Aciclovir enters herpes-infected cells and inhibits the herpes-specific DNA polymerase, stopping further viral DNA synthesis and therefore replication.
- Main indications =
1) Treatment of acute episodes of herpesvirus infections, including herpes simplex (e.g. cold sores, genital ulcers, encephalitis) and varicella-zoster (e.g. chickenpox, shingles).
2) Suppression of recurrent herpes simplex attacks where these are occurring at a frequency of 6 or more per year. - Contraindications = Aciclovir has no major contraindications. It does cross the placenta and is expressed in breast milk, so caution is advised in *pregnant women and women who are *breastfeeding. However, infections such as viral encephalitis, varicella pneumonia, and genital herpes carry significant risks to the mother and foetus, so the benefits of treatment in such circumstances are likely to outweigh its risks. Aciclovir is excreted by the kidneys; the dose and/or frequency of administration should therefore be reduced in *severe renal impairment to prevent accumulation of the drug and subsequent toxicity.
- Route of admin = oral, IV infusion
- Adverse effects = Common adverse effects include headache, dizziness, GI upset, and skin rash. IV aciclovir can cause inflammation or phlebitis at the injection site. Aciclovir is relatively water insoluble. During high-dose IV therapy, delivery of a high concentration of aciclovir into the renal tubules can cause precipitation, leading to crystal-induced acute renal failure. The risk of this can be minimised by ensuring good hydration and slowing the rate of infusion.
- Examples = Aciclovir
Beta blockers
- Mechanism of action = Via β1-adrenoreceptors, which are located mainly in the heart, β-blockers reduce force of cardiac contraction and speed of conduction. In IHD, this reduces cardiac work and oxygen demand and increases myocardial perfusion. In chronic heart failure, it improves prognosis probably by ‘protecting’ the heart from chronic sympathetic stimulation. In AF, it reduces ventricular rate by prolonging the refractory period of the atrioventricular (AV) node, and therefore the proportion of fibrillation waves that are conducted. By the same effect, β-blockers may terminate SVT if this is due to a self-perpetuating (‘re-entry’) circuit. The blood pressure-lowering effect of β-blockers is complex, likely involving reduced β1-mediated renin secretion from the kidney. Their action in migraine is thought to be via modulation of neuronal excitability in the brain, perhaps through reduced firing in noradrenergic neurons. In thyrotoxicosis, they offset the effect of β-adrenoreceptor upregulation, which causes symptoms such as tremor and palpitations. An additional effect (particularly with propranolol) is inhibition of monodeiodinase, reducing conversion of thyroxine (T4) to triiodothyronine (T3), but the clinical importance of this is doubtful.
- Main indications =
1) Ischaemic heart disease (IHD): to improve symptoms and prognosis in angina and acute coronary syndrome (ACS).
2) Chronic heart failure: to improve prognosis.
3) Atrial fibrillation (AF): to reduce the ventricular rate and, in paroxysmal AF, to maintain sinus rhythm.
4) Supraventricular tachycardia (SVT): to restore sinus rhythm.
5) Resistant hypertension: as a fourth-line treatment option.
6) Prophylaxis of migraine: other options are amitriptyline, valproate, and drugs targeting calcitonin gene-related peptide (e.g. galcanezumab).
7) Thyrotoxicosis: for symptoms caused by sympathetic stimulation. - Contraindications = In *asthma, β-blockers can cause life-threatening bronchospasm and should be avoided. This effect is mediated via β2-adrenoreceptors located in smooth muscle of the airways. β-blockers are usually safe in COPD, but it is prudent to choose a relatively β1-selective option (e.g. bisoprolol, metoprolol). In *heart failure, β-blockers should be started at a low dose and increased slowly, as they may initially impair cardiac function. They are contraindicated in *heart block and severe *hypotension and generally require dosage reduction in significant *hepatic failure.
- Route of admin = Oral, Intravenous injection
- Adverse effects = Fatigue, cold extremities, headache, and GI upset are common. β-blockers can also cause sleep disturbance, nightmares, and impotence.
- Examples = bisoprolol, atenolol, propranolol, metoprolol, carvedilol
Angiotensin-converting enzyme (ACE) inhibitor
- Mechanism of action = ACE inhibitors inhibit the action of angiotensin-converting enzyme (ACE), reducing conversion of angiotensin I to angiotensin II. Angiotensin II is a vasoconstrictor and stimulates aldosterone secretion. Blocking its action reduces peripheral vascular resistance (afterload), which lowers blood pressure (BP). It particularly dilates the efferent glomerular arteriole, which reduces intraglomerular pressure and slows the progression of CKD. Reducing aldosterone concentration promotes sodium and water excretion. This can help to reduce venous return (preload), which has a beneficial effect in heart failure.
- Main indications =
1) Hypertension: for first- or second-line treatment of hypertension, to reduce the risk of stroke, myocardial infarction, and death from cardiovascular disease.
2) Chronic heart failure: for first-line treatment of all grades of heart failure, to improve symptoms and prognosis.
3) Secondary prevention of major adverse cardiovascular events in people with ischaemic heart disease, cerebrovascular disease, or peripheral vascular disease.
4) Diabetic nephropathy and chronic kidney disease (CKD) with proteinuria: to reduce proteinuria and progression of nephropathy. - Contraindications = ACE inhibitors should be avoided in ✖ renal artery stenosis and ✖ acute kidney injury; in women who are, or could become, ▲ pregnant; or who are ▲breastfeeding. ACE inhibitors are valuable in the treatment of ▲ CKD, but lower doses should be used, and renal function monitored closely (see MONITORING).
- Route of admin = oral (best to take the first dose before bed to reduce symptomatic hypotension)
- Adverse effects = Common side effects include hypotension (particularly after the first dose), and hyperkalaemia (because a lower aldosterone level promotes potassium retention). They can cause or worsen renal failure. Renal artery stenosis presents a particular risk, as constriction of the efferent glomerular arteriole is required to maintain glomerular filtration. If detected early, these adverse effects are usually reversible on stopping the drug. Dry cough is also common and caused by increased levels of bradykinin (which is inactivated by ACE). An angiotensin receptor blocker is an alternative if this occurs. Rare but important side effects of ACE inhibitors include angioedema and other anaphylactoid reactions.
- Examples = ramipril, lisinopril, perindopril
β2-agonists
- Mechanism of action = β2-receptors are found in smooth muscle of the bronchi, gut, uterus, and blood vessels. Stimulation of these G protein-coupled receptors activates a signalling cascade that leads to smooth muscle relaxation and bronchodilation. This improves airflow, reducing breathlessness. Like insulin, β2-agonists also stimulate Na+/K+-adenosine triphosphatase (ATPase) pumps on cell membranes, shifting K+ from the extracellular to intracellular compartment. This can cause the adverse effect of hypokalaemia, but may also have therapeutic benefit as an adjunct to other treatments for hyperkalaemia, particularly if IV access is difficult. β2-agonists are classified as short-acting (SABAs, e.g. salbutamol, terbutaline) or long-acting (LABAs, e.g. salmeterol, formoterol) according to their duration of effect. SABAs, which have a fast onset of action (within 5minutes), are used to relieve acute breathlessness. LABAs are used as maintenance (preventer) therapy. Taken regularly for COPD, LABAs also reduce exacerbations.
- Main indications =
1) Asthma: short-acting β2-agonists (SABAs) are used to relieve bronchospasm during acute asthma attacks, and for intermittent breathlessness or wheeze in chronic asthma. Long-acting β2-agonists (LABAs) are added to inhaled corticosteroids (ICS) in chronic asthma if symptoms are uncontrolled by an ICS alone.
2) COPD: SABAs are used to relieve breathlessness and exercise limitation. If a SABA is insufficient, a LABA is recommended as first-line regular therapy. Depending on whether the person does, or does not, have features of asthma or steroid responsiveness, the LABA is combined with either a long-acting antimuscarinic (LAMA) or an inhaled corticosteroid, respectively. - Contraindications = When used for Uncomplicated premature labour under specialist supervision with intravenous use, Abruptio placenta (in adults); antepartum haemorrhage (in adults); cord compression (in adults); eclampsia (in adults); history of cardiac disease (in adults); intra-uterine fetal death (in adults); intra-uterine infection (in adults); placenta praevia (in adults); pulmonary hypertension (in adults); severe pre-eclampsia (in adults); significant risk factors for myocardial ischaemia (in adults); threatened miscarriage (in adults)
- Route of admin = The inhaler type should be selected according to the needs and capabilities of the individual. Aerosol (metered dose) inhalers (MDIs) require coordination, while dry powder inhalers (DPIs) require forceful inspiration. Training on inhaler technique is essential and should be checked at every visit.
- Adverse effects = Activation of β2-receptors in diverse tissues accounts for the common ‘fight or flight’ adverse effects of tachycardia, palpitations, anxiety, tremor, and headache. β2-agonists can cause hypokalaemia and elevate serum lactate, particularly at high doses. They promote glycogenolysis, so may cause hyperglycaemia. LABAs can cause muscle cramps.
- Examples = salbutamol, formoterol, salmeterol, indacaterol
Aldosterone antagonists
- Mechanism of action = Aldosterone is a mineralocorticoid that is produced in the adrenal cortex. It acts on mineralocorticoid receptors in the distal tubules of the kidney to increase the activity of luminal epithelial sodium (Na+) channels (ENaC). This increases the reabsorption of sodium and water, elevating blood pressure, with a corresponding increase in potassium excretion. Aldosterone antagonists inhibit the effect of aldosterone by competitive inhibition at mineralocorticoid receptors. This increases sodium and water excretion and potassium retention. Their effect is greatest when circulating aldosterone is increased, e.g. in primary hyperaldosteronism or cirrhosis.
- Main indications =
1) Ascites and oedema due to liver cirrhosis: spironolactone is the first-line diuretic in this indication.
2) Chronic heart failure: of at least moderate severity or arising within 1month of a myocardial infarction, usually as an addition to a β-blocker and an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker.
3) Primary hyperaldosteronism: while awaiting surgery, or if surgery is not an option. - Contraindications = Aldosterone antagonists are contraindicated in ✖ severe renal impairment, ✖ hyperkalaemia, and ✖ adrenal insufficiency. Aldosterone antagonists can cross the placenta during pregnancy and appear in breast milk so should be avoided where possible in ▲ pregnant or lactating women.
- Route of admin = Oral (Spironolactone should generally be taken with food).
- Adverse effects = An important adverse effect of aldosterone antagonists is hyperkalaemia, which can lead to muscle weakness, arrhythmias, and even cardiac arrest. Spironolactone causes gynaecomastia (enlargement of male breast tissue), which can have a significant impact on adherence in men (see COMMUNICATION). Eplerenone is less likely to cause endocrine side effects. Aldosterone antagonists can cause liver impairment and jaundice and spironolactone is a cause of Stevens–Johnson syndrome (a T-cell-mediated hypersensitivity reaction) that causes a bullous skin eruption.
- Examples = spironolactone, eplerenone
Digoxin
- Mechanism of action = Digoxin is negatively chronotropic (it reduces the heart rate) and positively inotropic (it increases the force of contraction). In AF and flutter, its therapeutic effect arises mainly via an indirect pathway involving increased vagal (parasympathetic) tone. This reduces conduction at the atrioventricular (AV) node, preventing some impulses from being transmitted to the ventricles, thereby reducing the ventricular rate. In heart failure, it has a direct effect on myocytes through inhibition of Na+/K+-ATPase pumps, causing Na+ to accumulate in the cell. As cellular extrusion of Ca2+ requires low intracellular Na+ concentrations, elevation of intracellular Na+ causes Ca2+ to accumulate in the cell, increasing contractile force.
- Main indications =
1) In atrial fibrillation (AF) and atrial flutter, digoxin is used to reduce the ventricular rate. However, a β-blocker or non-dihydropyridine calcium channel blocker is usually more effective.
2) In severe heart failure, digoxin may be added if treatment with an ACE inhibitor, β-blocker and either an aldosterone antagonist or angiotensin receptor blocker is insufficient, or at an earlier stage if there is co-existing AF. - Contraindications = Digoxin may worsen conduction abnormalities, so is contraindicated in ✖ second-degree heart block and ✖ intermittent complete heart block. It should not be used in those with or at risk of ✖ ventricular arrhythmias. The dose should be reduced in ▲ renal failure, as digoxin is eliminated by the kidneys. Certain electrolyte abnormalities increase the risk of digoxin toxicity, including ▲ hypokalaemia, ▲ hypomagnesaemia, and ▲ hypercalcaemia. Potassium disturbance is probably the most important of these, as digoxin competes with potassium to bind the Na+/K+-ATPase pump. When serum potassium levels are low, competition is reduced and the effects of digoxin are enhanced.
- Route of admin = Oral digoxin can be taken with or without food. Intravenous doses must be given slowly.
- Adverse effects = bradycardia, GI upset, rash, dizziness, and visual disturbance (blurred or yellow vision). Digoxin is proarrhythmic and has a low therapeutic index: that is, the safety margin between the therapeutic and toxic doses is narrow. A wide range of arrhythmias can occur in digoxin toxicity and these may be life threatening.
- Examples = digoxin
Diuretics, loop
- Mechanism of action = As their name suggests, loop diuretics act principally on the ascending limb of the loop of Henle, where they inhibit the Na+/K+/2Cl− co-transporter. This protein is responsible for transporting sodium, potassium, and chloride ions from the tubular lumen into the epithelial cell. Water then follows by osmosis. Inhibiting this process has a potent diuretic effect. In addition, loop diuretics have a direct effect on blood vessels, causing dilation of capacitance veins. In acute heart failure, this reduces preload and improves contractile function of the ‘overstretched’ heart muscle. Indeed, this is probably the main benefit of loop diuretics in acute heart failure, as illustrated by the fact that a clinical response usually occurs before diuresis is evident.
- Main indications =
1) For relief of breathlessness in acute pulmonary oedema in conjunction with oxygen and nitrates.
2) For symptomatic treatment of fluid overload in chronic heart failure.
3) For symptomatic treatment of fluid overload in other oedematous states, e.g. due to renal disease or liver failure, where they may be given in combination with other diuretics. - Contraindications = Loop diuretics are contraindicated in severe ✖ hypovolemia and ✖ dehydration. They should be used with caution in ▲ hypokalaemia, ▲ hyponatraemia and in people at risk of ▲ hepatic encephalopathy (where hypokalaemia can cause or worsen coma). In chronic use, loop diuretics inhibit uric acid excretion, which can worsen ▲ gout.
- Route of admin = Oral, IV
- Adverse effects = Water losses due to diuresis can lead to dehydration and hypotension. Inhibiting the Na+/K+/2Cl− co-transporter increases urinary losses of sodium, potassium, and chloride ions. Indirectly, this also increases excretion of magnesium, calcium, and hydrogen ions. You can therefore associate loop diuretics with almost any low electrolyte state (i.e. hyponatraemia, hypokalaemia, hypochloraemia, hypocalcaemia, hypomagnesaemia, and metabolic alkalosis). Hypernatremia may also occur, due to loss of water in excess of sodium. A similar Na+/K+/2Cl− co-transporter is responsible for regulating endolymph composition in the inner ear. At high doses, loop diuretics can affect this too, leading to hearing loss and tinnitus.
- Examples = furosemide, bumetanide
Statins
- Mechanism of action = Statins slow the atherosclerotic process and may even reverse it. They act by competitive inhibition of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, the enzyme that catalyses the rate-limiting step in cholesterol synthesis. This reduces cholesterol production by the liver and stimulates a compensatory increase in low-density lipoprotein (LDL) cholesterol uptake from the blood by hepatocytes. Together, these effects reduce LDL cholesterol levels and also, indirectly, reduce triglycerides and slightly increase high-density lipoprotein (HDL) cholesterol levels. In addition to their lipid-lowering effects, statins may modulate the inflammatory response and improve endothelial function. These effects may be due to reduced production of isoprenoid intermediates in the cholesterol synthesis pathway, which are substrates in the production of various cell-signalling proteins.
- Main indications =
1) Primary prevention of major adverse cardiovascular events (e.g. myocardial infarction, stroke) in people over 40years of age with a 10-year cardiovascular risk >10%, as assessed using a validated tool.
2) Secondary prevention of major adverse cardiovascular events in people with ischaemic heart disease (including after acute coronary syndrome), stroke, and peripheral vascular disease.
3) Dyslipidaemia (e.g. primary hypercholesterolaemia, mixed dyslipidaemia, familial hypercholesterolaemia). - Contraindications = Statins should be used with caution in ▲ hepatic impairment. With the exception of rosuvastatin, statins are dependent on the kidneys for elimination of their metabolites, so the dose should be reduced in ▲ renal impairment. Statins are contraindicated for women who are ▲ pregnant (cholesterol is essential for normal fetal development) and should be avoided in ▲ breastfeeding.
- Route of admin = Oral; Simvastatin, which has a short half-life, is best taken in the evening, because cholesterol synthesis is greatest in the early-morning hours. This is not necessary for other statins that have a longer half-life.
- Adverse effects = Statins are generally safe and well tolerated. The most common adverse effects are headache, GI upset, and muscle aches. Rare but more serious adverse effects are myopathy and rhabdomyolysis. Statins can cause a rise in liver enzymes (e.g. alanine transaminase). Minor biochemical changes are clinically unimportant (see MONITORING), but drug-induced hepatitis is a rare but serious adverse effect.
- Examples = atorvastatin, simvastatin, rosuvastatin, pravastatin
Calcium channel blockers
- Mechanism of action = Calcium channel blockers decrease calcium ion (Ca2+) entry into vascular and cardiac cells, reducing intracellular calcium concentration. This causes relaxation and vasodilation in arterial smooth muscle, lowering arterial pressure. In the heart, calcium channel blockers reduce myocardial contractility. They suppress cardiac conduction, particularly across the atrioventricular (AV) node, slowing ventricular rate. Reduced ventricular rate, contractility, and afterload reduce myocardial oxygen demand, preventing angina. Calcium channel blockers can broadly be divided into two classes. Dihydropyridines, including amlodipine and nifedipine, are relatively selective for the vasculature, whereas non-dihydropyridines are more selective for the heart. Of the non-dihydropyridines, verapamil is the most cardioselective, whereas diltiazem also has some effects on blood vessels.
- Main indications =
1) Amlodipine and, to a lesser extent, nifedipine are used for the first- or second-line treatment of hypertension, to reduce the risk of stroke, myocardial infarction, and death from cardiovascular disease.
2) All calcium channel blockers can be used to control angina in people with ischaemic heart disease; β-blockers are the main alternative.
3) Diltiazem and verapamil are used to control heart rate in people with supraventricular arrhythmias, including supraventricular tachycardia, atrial flutter, and atrial fibrillation.
- Contraindications = Verapamil and diltiazem should be used with caution in ▲ impaired left ventricular function, as they can precipitate or worsen heart failure. They should generally be avoided in ▲ AV nodal conduction delay, as they may provoke complete heart block. Amlodipine and nifedipine should be avoided in ✖ unstable angina as vasodilation causes a reflex increase in contractility and tachycardia, which increases myocardial oxygen demand. In ✖ severe aortic stenosis, amlodipine and nifedipine should be avoided as they can cause collapse.
- Route of admin = Oral
- Adverse effects = Common adverse effects of amlodipine and nifedipine include ankle swelling, flushing, headache, and palpitations, which are caused by vasodilation and compensatory tachycardia. Verapamil commonly causes constipation and less often, but more seriously, bradycardia, heart block, and cardiac failure. As diltiazem has mixed vascular and cardiac actions, it can cause any of these adverse effects.
- Examples = amlodipine, felodipine, nifedipine, diltiazem, verapamil
Nitrofurantoin
- Mechanism of action = Nitrofurantoin is metabolised (reduced) in bacterial cells by nitrofuran reductase. Its active metabolite damages bacterial DNA and causes cell death (bactericidal). Bacteria with lower nitrofuran reductase activity are resistant to nitrofurantoin. Some organisms that are less common causes of UTI (such as Klebsiella and Proteus species) have intrinsic resistance to nitrofurantoin. It is relatively rare for E. coli to acquire nitrofurantoin resistance. Nitrofurantoin requires concentration in the urine by renal excretion for therapeutic effect against UTIs; for the same reason, it is not useful for infections elsewhere in the body. Nitrofurantoin is active against most organisms that cause uncomplicated UTIs, including Escherichia coli (Gram-negative) and Staphylococcus saprophyticus (Gram-positive).
- Main indications =
1) Nitrofurantoin is a first-line option for acute, uncomplicated lower urinary tract infection (UTI) (an alternative is trimethoprim).
2) Prophylaxis of recurrent UTIs. - Contraindications = Nitrofurantoin should not be prescribed for ✖ pregnant women towards term, for ✖ babies in the first 3months of life or for people with ✖ G6PD deficiency because of the risk of haemolysis. It is contraindicated in ✖ renal impairment, as impaired excretion increases toxicity and reduces efficacy due to lower urinary drug concentrations. Caution is required when using nitrofurantoin for ▲ long-term prevention of UTIs, as chronic use increases the risk of pulmonary, hepatic and neurological adverse effects, particularly in older people.
- Route of admin = Oral nitrofurantoin is available as tablets, immediate- or modified-release capsules and in suspension. It should be taken with food or milk to minimise GI effects. There is no parenteral formulation.
- Adverse effects = As with many antibiotics, nitrofurantoin can cause GI upset and immediate and delayed hypersensitivity reactions (see Penicillins, broad-spectrum). Nitrofurantoin, specifically, can turn urine dark yellow or brown. Less commonly, it may cause chronic pulmonary reactions (including inflammation (pneumonitis) and fibrosis), hepatitis, and peripheral neuropathy, which all are more likely with prolonged administration. In neonates, haemolytic anaemia may occur because immature red blood cells are unable to mop up nitrofurantoin-stimulated superoxides, which damage red blood cells.
- Examples = nitrofurantoin
Angiotensin receptor blockers (ARBs)
- Mechanism of action = ARBs have similar effects to angiotensin-converting enzyme (ACE) inhibitors, but instead of inhibiting the conversion of angiotensin I to angiotensin II, ARBs block the action of angiotensin II on the angiotensin type 1 (AT1) receptor. Angiotensin II is a vasoconstrictor and stimulates aldosterone secretion. Blocking its action reduces peripheral vascular resistance (afterload), which lowers blood pressure. It particularly dilates the efferent glomerular arteriole, which reduces intraglomerular pressure and slows the progression of CKD. Reducing aldosterone concentration promotes sodium and water excretion. This can help to reduce venous return (preload), which has a beneficial effect in heart failure.
- Main indications =
1) Hypertension: for first- or second-line treatment of hypertension, to reduce the risk of stroke, myocardial infarction, and death from cardiovascular disease.
2) Chronic heart failure: for first-line treatment of all stages of heart failure, to improve symptoms and prognosis.
3) Secondary prevention of major adverse cardiovascular events in people with ischaemic heart disease, cerebrovascular disease or peripheral vascular disease.
4) Diabetic nephropathy and chronic kidney disease (CKD) with proteinuria: to reduce proteinuria and progression of nephropathy. - Contraindications = ARBs should be avoided in ✖ renal artery stenosis and ✖ acute kidney injury; in women who are, or could become, ▲ pregnant; or who are ▲ breastfeeding. ARBs are valuable in the treatment of ▲ CKD, but lower doses should be used, and renal function monitored closely.
- Route of admin = Oral; ARBs can be taken with or without food. It is best to take the first dose before bed to reduce symptomatic hypotension.
- Adverse effects = ARBs can cause hypotension (particularly after the first dose), hyperkalaemia, and renal failure. The mechanism is the same as for ACE inhibitors. Renal artery stenosis presents a particular risk, as constriction of the efferent glomerular arteriole is required to maintain glomerular filtration. ARBs are less likely than ACE inhibitors to cause cough and angioedema, as they do not inhibit ACE, so do not affect bradykinin metabolism. They may therefore preferred in Black people of African or Caribbean origin, who are at higher risk of angioedema.
- Examples = losartan, candesartan, irbesartan
Antimuscarinics, genitourinary uses
- Mechanism of action = Antimuscarinic drugs bind to muscarinic receptors, where they act as a competitive inhibitor of acetylcholine. Contraction of the smooth muscle of the bladder is under parasympathetic control. Blocking muscarinic receptors therefore promotes bladder relaxation, increasing bladder capacity. In overactive bladder, this may reduce urinary frequency, urgency, and urge incontinence. Antimuscarinics work in overactive bladder through antagonism at the M3 receptor, which is the main muscarinic receptor subtype in the bladder. Solifenacin is more selective for the M3 receptor, which may reduce side effects caused by actions on other muscarinic receptor subtypes (see Antimuscarinics, cardiovascular and GI uses).
- Main indications =
1) To reduce urinary frequency, urgency and urge incontinence in overactive bladder, as a first-line pharmacological treatment if bladder training is ineffective. - Contraindications = Antimuscarinics are contraindicated in ✖ urinary tract infection. Urinalysis is therefore an important part of assessment before prescribing treatment for overactive bladder. Cognitive effects can be particularly problematic in ▲ older people and those with ▲ dementia. Antimuscarinics should be used with caution in people susceptible to ▲ angle-closure glaucoma, in whom they can precipitate a dangerous rise in intraocular pressure. They should be used with caution in people at risk of ▲ arrhythmias (e.g. those with significant cardiac disease) and, for obvious reasons, those at risk of ▲ urinary retention.
- Route of admin = Oral; Immediate-release antimuscarinics should be taken at roughly equal intervals, with or without food. MR forms should be taken at a similar time each day and swallowed whole, not chewed.
- Adverse effects = Predictably from their antimuscarinic action, dry mouth is a very common side effect of these drugs. Other classic antimuscarinic side effects such as tachycardia, constipation, and blurred vision are also common. Urinary retention may occur if there is bladder outflow obstruction. Cognitive effects (e.g. drowsiness, confusion) are most problematic with oxybutynin, because it is lipid soluble (so readily crosses the blood–brain barrier) and also acts on the M1 receptor (which is widely distributed in the brain).
- Examples = solifenacin, oxybutynin, tolterodine
Antidepressants, selective serotonin reuptake inhibitors
- Mechanism of action = Selective serotonin reuptake inhibitors (SSRIs) preferentially inhibit neuronal reuptake of 5-hydroxytryptamine (serotonin) (5-HT) from the synaptic cleft, thereby increasing its availability for neurotransmission. This appears to be the mechanism by which SSRIs improve mood and physical symptoms in depression and relieve symptoms of panic and obsessive disorders. SSRIs differ from tricyclic antidepressants in that they do not inhibit noradrenaline uptake and cause less blockade of other receptors. The efficacy of the two drug classes in the treatment of depression is similar. However, SSRIs are generally preferred as they have fewer adverse effects and are less dangerous in overdose.
- Main indications =
1) As first-line treatment for moderate-to-severe depression, and in mild depression if psychological treatments alone are insufficient.
2) Panic disorder.
3) Obsessive compulsive disorder. - Contraindications = Caution is required in ▲ epilepsy and ▲ peptic ulcer disease. In ▲ young people, SSRIs have poor efficacy and are associated with an increased risk of self-harm and suicidal thoughts, so should be prescribed by specialists only. As SSRIs are metabolised by the liver, dose reduction may be required in people with ▲ hepatic impairment.
- Route of admin = tablets and as oral drops, which can be mixed with water or other drinks.
- Adverse effects = Common adverse effects include GI upset, changes in appetite and weight (loss or gain), and hypersensitivity reactions, including skin rash. Hyponatraemia is an important adverse effect, particularly in older people, and may present with confusion and reduced consciousness. Suicidal thoughts and behaviour may be associated with SSRIs. They may lower the seizure threshold, though the evidence for this is conflicting. Some (e.g. citalopram) can prolong the QT interval, predisposing to arrhythmias. SSRIs also increase the risk of bleeding. At high doses, in overdose or in combination with other serotonergic drugs (e.g. other antidepressants, tramadol), SSRIs can cause serotonin syndrome. This triad of autonomic hyperactivity, altered mental state, and neuromuscular excitation usually responds to treatment withdrawal and supportive therapy. Sudden withdrawal of SSRIs can cause GI upset, neurological and flu-like symptoms, and sleep disturbance.
- Examples = sertraline, citalopram, fluoxetine, escitalopram
Opioids
- Mechanism of action = Opioids include naturally occurring opiates (e.g. morphine) and their synthetic analogues (e.g. oxycodone). The therapeutic effects of opioids are mediated by agonism of opioid µ (mu) receptors in the central nervous system (CNS). Activation of these G protein-coupled receptors has several effects that, overall, reduce neuronal excitability and pain transmission. In the medulla, they blunt the response to hypoxia and hypercapnoea, reducing respiratory drive and breathlessness. By relieving pain, breathlessness, and associated anxiety, opioids reduce sympathetic nervous system (fight or flight) activity. In acute coronary syndrome and pulmonary oedema, this reduces cardiac work and oxygen demand. In practical use, opioids are classified by strength. This refers to the intensity of effect that can be elicited with typical therapeutic doses. For example, morphine and oxycodone are strong opioids, while codeine and dihydrocodeine are weak. The latter examples are prodrugs—they are metabolised in the liver to more active metabolites (including morphine and dihydromorphine, respectively). Tramadol is a synthetic analogue of codeine. It is perhaps best classified as having moderate strength. In addition to agonism of the µ receptor, it inhibits neuronal noradrenaline and serotonin uptake. This contributes to analgesia by potentiating descending inhibitory pain pathways.
- Main indications =
1) Acute pain, e.g. in trauma, surgery or acute coronary syndrome.
2) Chronic pain, as part of a multimodal approach, if non-pharmacological treatments, paracetamol, NSAIDs, and adjuvant analgesics (e.g. pregabalin) are insufficient.
3) Breathlessness in palliative care.
4) Acute pulmonary oedema, alongside oxygen, furosemide, and nitrates. - Contraindications = Most opioids rely on the liver and the kidneys for elimination, so doses should be reduced in ▲ hepatic failure and ▲ renal impairment and in ▲ older people. Do not give opioids in ▲ respiratory failure except under senior guidance (e.g. in palliative care).
- Route of admin = IV, oral
- Adverse effects = Opioids may cause respiratory depression, euphoria, detachment, and in higher doses, neurological depression. They can activate the chemoreceptor trigger zone, causing nausea and vomiting. Pupillary constriction occurs due to stimulation of the Edinger–Westphal nucleus. Activation of µ receptors increases intestinal smooth muscle tone and reduces motility, leading to constipation. Opioids may cause histamine release, leading to itching, urticaria, vasodilation, and sweating. Prolonged use can lead to dependence and hyperalgesia.
- Examples = morphine, oxycodone (strong) codeine, dihydrocodeine, tramadol (weak/moderate)
Serotonin 5-HT1-receptor agonists (triptans)
- Mechanism of action = Serotonin 5-HT1-receptor agonists relieve the symptoms of acute migraine, including headache and nausea. Although the mechanisms underlying migraine are not completely understood, the primary disturbance is thought to be a slowly propagating wave of cortical depolarisation (cortical spreading depression). This is associated with local vasoconstriction and, depending on the area of the brain affected, may cause early focal neurological symptoms (aura). Subsequently, activation of trigeminal nerve afferents that innervate cerebral blood vessels and the meninges (the trigeminovascular pathway) causes release of vasoactive peptides such as calcitonin gene-related peptide (CGRP). This, in turn, simulates neurogenic inflammation and dilation of cranial blood vessels, causing headache and other symptoms of acute migraine. Triptans are thought to act by inhibiting neurotransmission in the peripheral trigeminal nerve and in the trigeminocervical complex (via 5-HT1B and 5-HT1D receptors) and constricting cranial blood vessels (via 5-HT1B receptors).
- Main indications =
1) In acute migraine with or without aura, serotonin 5-HT1-receptor agonists, often referred to as ‘triptans’, are used to reduce the duration and severity of symptoms. Paracetamol and NSAIDs are alternative options and may be combined with triptans. - Contraindications = Due to their vasoconstrictor properties these drugs should not be used in ✖ ischaemic heart disease, ✖ cerebrovascular disease, ✖ peripheral vascular disease, and ✖ uncontrolled hypertension. Triptans should also not be used in ✖ hemiplegic migraine or ✖ migraine with brainstem aura (e.g. with vertigo or diplopia).
- Route of admin = tablets, nasal spray
- Adverse effects = Common adverse effects of triptans include chest and throat discomfort, which can be intense but resolves quickly. Rarely, triptans can cause angina and myocardial infarction due to coronary vasospasm. Other common adverse effects include nausea and vomiting, tiredness, dizziness, and transient high blood pressure. In general, adverse effects are more common with SC administration of sumatriptan than with other drugs by other routes.
- Examples = sumatriptan, zolmitriptan
Oestrogens and progestogens
- Mechanism of action = Luteinising hormone (LH) and follicle-stimulating hormone (FSH) control ovulation and ovarian production of oestrogen and progesterone. In turn, oestrogen and progesterone exert predominantly negative feedback on LH and FSH release. In hormonal contraception, oestrogens (e.g. ethinylestradiol) and/or progestogens (e.g. desogestrel) are given to suppress LH/FSH release and hence ovulation. Oestrogens and progestogens also have effects outside the ovary. Some, such as in the cervix and endometrium, may contribute to their contraceptive effect (most relevant in progestogen-only contraception). Others offer additional benefits, e.g. reduced menstrual pain and bleeding, and improvements in acne. At the menopause, a fall in oestrogen and progesterone levels may generate symptoms such as vaginal dryness and vasomotor instability (‘hot flushes’). Oestrogen replacement (usually combined with a progestogen) alleviates these.
- Main indications =
1) Hormonal contraception in those requiring highly effective, reversible contraception, particularly if its other effects (e.g. improved acne control) are also desirable.
2) Hormone replacement therapy (HRT) to delay early menopause and treat distressing menopausal symptoms (any age). Systemic formulations (tablets or patches) are used for systemic symptoms (e.g. hot flushes), and vaginal gels for vaginal symptoms (e.g. dryness). - Contraindications = Oestrogens and progestogens are contraindicated in women with ✖ breast cancer. CHC should be avoided in those with a ✖ personal or ▲ family history of VTE; ✖ thrombogenic mutation; or risk factors for ▲ cardiovascular disease (including age >35years; migraine with aura; heavy smoking history). Women who have a uterus should not receive oestrogen-only HRT, due to the risk of endometrial benign prostatic enlargement.
- Route of admin = Oral
- Adverse effects = Hormonal contraception may cause irregular bleeding and mood changes. It does not appear to cause weight gain. The oestrogens in combined hormonal contraception (CHC) double the risk of venous thromboembolism (VTE), but the absolute risk is low. They increase the risk of cardiovascular disease and stroke, most relevant in women with other vascular risk factors. They may be associated with increased risk of breast and cervical cancer. In both cases the effect is small, and for breast cancer, it gradually resolves after stopping the pill. Progestogen-only pills do not increase the risk of VTE or cardiovascular disease. The adverse effects of HRT are similar to those of CHC but, as baseline rates of disease are higher, the relative risks have more significant effects.
- Examples = ethinylestradiol, estradiol (oestrogens) levonorgestrel, desogestrel (progestogens)
Direct oral anticoagulants
- Mechanism of action = The coagulation cascade is a series of reactions triggered by vascular injury that generates a fibrin clot. The DOACs act on the final common pathway of the coagulation cascade, comprising factor X, thrombin, and fibrin. ApiXaban, edoXaban, and rivaroXaban directly inhibit activated factor X (Xa), preventing conversion of prothrombin to thrombin. Dabigatran directly inhibits thrombin, preventing the conversion of fibrinogen to fibrin. All DOACs therefore inhibit fibrin formation, preventing clot formation or extension in the veins and heart. They are less effective in the arterial circulation where dols a largely platelet driven, and are better prevented by antiplatelet agents.
- Main indications =
1) VTE = treatment and prevention of recurrence (secondsry prevention) of VTE. Heparin and warfarin are alternatives. DOACs are also indicated as primary prevention if VTE in elective surgeries.
2) Atrial Fibrillation = DOACs are indicated to prevent stroke and systemic emboism in non-valvular AF associated with at least one risk factor (including previous stroke, symptomatic heart failure, diabetes mellitus, or hypertension). Warfarin is an alternative. - Contraindications = DOACs should be avoided in people with *active, clinically significant bleeding and in those with *risk factors for major bleeding, such as peptic ulceration, cancer, and recent surgery or trauma, particularly of the brain, spine or eye. As DOACs are excreted by multiple routes, including cytochrome P450 (CYP) enzyme metabolsm and elimination in faeces and urine, dose reduction or an alternative agent may be required in *hepatic or *renal disease. DOACs are containdicated in *pregnancy and *breastfeeding, where the ridk of harm to the baby is unknown, but has been seen in animal studies. Risk of bleeding with DOACs is increased by concurrent therapy with other antithrombotic agents (e.g. *heparin, *antiplatelets, and *NSAIDs). Other interactions can arise with drugs that affect DOAC metabolism or excretion. E.g anticoagulant effect is increased by macrolides, protease inhibitors and fluconazole, but decreased by rifampicin and phenytoin.
- Route of admin = oral (rivaroxaban must be taken with food) which is advantageous over heparin (injection) in the outpatient setting.
- Adverse effects = Bleeding is an important adverse effect, most commonly epistaxis, Gl, and genitourinary haemorrhage. The risk of intracranial haemorrhage and major bleeding is less with DOACs than with warfarin. However, the risk of Gl bleeding is greater, possibly due to intraluminal drug accumulation causing local anticoagulant effects. Other adverse effects include anaemia, Gl upset, dizziness, and elevated liver enzymes.
- Examples = Apixaban, Rivaroxaban, Edoxaban, Dabigatran